Our experience with pancreatic graft extraperitoneal placement.
Adamec
M
M
Department of Hepatobiliary Sciences, King Fahad National Guard Hospital, Riyadh, Kingdom of Saudi Arabia.
Saudek
F
F
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D003928:Diabetic Nephropathies / Q000601:surgery; D004359:Drug Therapy, Combination; D004386:Duodenum / Q000601:surgery; D005260:Female; D006085:Graft Survival; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology; D008297:Male; D016035:Pancreas Transplantation / Q000379:methods* / Q000401:mortality / Q000502:physiology; D010529:Peritoneal Cavity; D011183:Postoperative Complications / Q000453:epidemiology; D015996:Survival Rate; D013997:Time Factors; D001743:Urinary Bladder / Q000601:surgery
D000925:Anticoagulants; D007166:Immunosuppressive Agents; D006493:Heparin; D001241:Aspirin